Prominex, Inc., a San Diego, CA-based molecular diagnostic company focused on point-of-care infectious disease testing, completed its $4m Series A-1 financing.
Backers included Casdin Capital and its founding CEO Paul Thomas.
The company intends to use the funds to advance the development of its infectious disease assays and commence an instrument development partnership with Invetech, a global leader in point-of-care instrument design and development.
Founded in 2016 by Thomas, Prominex focuses on the development of molecular diagnostic assays for point-of-care infectious disease testing. The novel molecular amplification and waveguide detection technologies incorporated into the Validex System enables the development of ultrafast multiplexed, and low-cost molecular diagnostic assays.